CD8A and renal cell carcinoma: In order to replicate the TME of RCC more accurately, we employed a preclinical model involving the implantation of RCC patient-derived xenografts into immunocompromised NCG mice, followed by the transfer of tumor-specific CD8+ T cells [34,35].